Infectious Disease Therapeutics Market Report 2026

Infectious Disease Therapeutics Market Overview

• Infectious Disease Therapeutics market size has reached to $150.6 billion in 2025 • Expected to grow to $200.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Infectious Diseases On The Upswing A Global Health Concern • Market Trend: Innovators Strengthen Infectious Disease Defense Through Multispecific Therapeutic Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Infectious Disease Therapeutics Market?

Infectious disease therapeutics refers to the various treatments and interventions aimed at combating illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. The goal of infectious disease therapeutics is to either eliminate the infectious agent from the body or to control its replication and spread, thereby alleviating symptoms, preventing complications, and ultimately promoting recovery. The main types of infectious disease therapeutics are drugs and vaccines. Vaccines are biological preparations that stimulate the immune system to recognize and fight specific infectious agents. The various diseases include tuberculosis, HIV/aids, influenza, hepatitis, and others that are used by various end-users such as hospitals and clinics, retail pharmacies, research organizations, and others.

What Is The Infectious Disease Therapeutics Market Growth Forecast?

The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $200.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising antimicrobial resistance rates, increasing frequency of infectious disease outbreaks, expansion of global vaccination coverage, growing demand for novel antiviral therapies, stronger public health preparedness initiatives. Major trends in the forecast period include rising focus on antimicrobial resistance management, increasing development of broad-spectrum therapeutics, growing adoption of combination drug therapies, expansion of rapid-response therapeutics for outbreaks, increased investment in vaccine research and stockpiling.

What Is The Driver Of The Infectious Disease Therapeutics Market?

The rising prevalence of infectious diseases is expected to propel the growth of the infectious disease therapeutics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. The rising infectious diseases are due to several key factors such as climate change and environmental disruption, antimicrobial resistance, weakened immune systems, increasing interactions with animals, and ecological disturbances. Infectious disease therapeutics play a vital role in treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases within communities and across populations. For instance, in October 2023, according to the National Health Service (NHS) England, a UK-based government department, in 2022/23, hospitals reported 147,285 admissions with a primary diagnosis of urinary tract infection (UTI). Patients aged over 65 represented 56% of these cases, amounting to 82,392 admissions. The 80–84 age group had the highest number of admissions, with 17,280 cases. Therefore, the rising prevalence of infectious diseases drives the infectious disease therapeutics industry.

Key Players In The Global Infectious Disease Therapeutics Market

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.

Global Infectious Disease Therapeutics Market Trends and Insights

Major companies operating in the infectious disease therapeutics market are focusing on incorporating multispecific antibody platforms such as the multispecific therapeutic antibody reactor (MSTAR) to enhance efficacy, broaden protection, and strengthen responsiveness to emerging viral threats. Multispecific therapeutic antibody reactor (MSTAR) is an advanced multispecific antibody technology that combines several independent binding regions into a single therapeutic molecule, enabling capabilities such as broad viral neutralization, simultaneous targeting of multiple epitopes, and rapid adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc, a US-based clinical stage biopharmaceutical company, secured a contract from the Biomedical Advanced Research and Development Authority to advance its multispecific antibody candidates designed for the treatment and prevention of viral infectious diseases including COVID 19 and influenza, featuring broad activity against circulating viral strains, potential compatibility with gene based delivery using mRNA or DNA vectors, and a multi binding site architecture. This multispecific antibody approach improves therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the complexity associated with combination biologic treatments.

What Are Latest Mergers And Acquisitions In The Infectious Disease Therapeutics Market?

In June 2023, Shionogi & Co., Ltd., a Japan-based pharmaceutical company, acquired Qpex Biopharma Inc. for an undisclosed amount. Through this acquisition, Shionogi aims to expand its infectious disease therapeutics portfolio by integrating Qpex’s advanced pipeline, including xeruborbactam, a first-in-class β-lactamase inhibitor designed to combat multidrug-resistant bacterial infections. Qpex Biopharma Inc. is a US-based clinical-stage biotechnology company specializing in the development of novel antimicrobial treatments for serious and drug-resistant infectious diseases.

What Defines the Infectious Disease Therapeutics Market?

The infectious disease therapeutics market consists of sales of antibiotics, antivirals, and immunotherapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Infectious Disease Therapeutics Market Report 2026?

The infectious disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.